Lead Product(s) : Itacitinib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Incyte Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients
Details : Itacitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Leukemia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 21, 2023
Lead Product(s) : Itacitinib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Incyte Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Itacitinib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Incyte Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy
Details : Itacitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lymphoma, Large B-Cell, Diffuse.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 07, 2023
Lead Product(s) : Itacitinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Incyte Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Itacitinib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Incyte Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Itacitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hematologic Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 21, 2022
Lead Product(s) : Itacitinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Incyte Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Itacitinib
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Itacitinib is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 30, 2022
Lead Product(s) : Itacitinib
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Itacitinib
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Incyte Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Treatment of Non Severe Hemophagocytosis Lymphohistiocytosis With ITACITINIB
Details : Itacitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lymphohistiocytosis, Hemophagocytic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 30, 2021
Lead Product(s) : Itacitinib
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Incyte Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Itacitinib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Itacitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Primary Myelofibrosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 23, 2020
Lead Product(s) : Itacitinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Itacitinib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Itacitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Primary Myelofibrosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 16, 2020
Lead Product(s) : Itacitinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Itacitinib
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Incyte Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Itacitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Graft vs Host Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 24, 2020
Lead Product(s) : Itacitinib
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Incyte Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Itacitinib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Incyte Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Itacitinib in Advanced Hepatocellular Carcinoma
Details : Itacitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Carcinoma, Hepatocellular.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 24, 2020
Lead Product(s) : Itacitinib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Incyte Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Itacitinib
Therapeutic Area : Immunology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Itacitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Graft vs Host Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 07, 2020
Lead Product(s) : Itacitinib
Therapeutic Area : Immunology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable